Symbols

GRCE

Grace Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GRCE

Grace Therapeutics, Inc.

A late-stage biopharma company with drug candidates addressing rare and orphan diseases

Industry

Pharmaceutical

Established Date

02/01/2002

Listing Date

01/07/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

03-31

Website

www.gracetx.com

Security Type

Common stock

Office address

103 Carnegie Center Suite 300, Princeton, New Jersey 08540

Business

Introduction

Grace Therapeutics, Inc., was established on February 1, 2002. They focus on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes through the use of their novel drug delivery technologies. They seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, easier drug delivery and improved patient compliance.

Company Financials

EPS

GRCE has released its 2026 Q2 earnings. EPS was reported at -0.06, versus the expected -0.24245881765686, beating expectations. The chart below visualizes how GRCE has performed over recent quarters, highlighting trends in earnings surprises.